HRP20191420T1 - Miševi koji su genetski modificirani s glavnim histokompatibilnim kompleksom - Google Patents
Miševi koji su genetski modificirani s glavnim histokompatibilnim kompleksom Download PDFInfo
- Publication number
- HRP20191420T1 HRP20191420T1 HRP20191420T HRP20191420T1 HR P20191420 T1 HRP20191420 T1 HR P20191420T1 HR P20191420 T HRP20191420 T HR P20191420T HR P20191420 T1 HRP20191420 T1 HR P20191420T1
- Authority
- HR
- Croatia
- Prior art keywords
- polypeptide
- human
- mhc
- hla
- nucleic acid
- Prior art date
Links
- 108700018351 Major Histocompatibility Complex Proteins 0.000 title 1
- 241000699670 Mus sp. Species 0.000 title 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 claims 39
- 102000004196 processed proteins & peptides Human genes 0.000 claims 24
- 108090000765 processed proteins & peptides Proteins 0.000 claims 24
- 150000007523 nucleic acids Chemical class 0.000 claims 15
- 108020004707 nucleic acids Proteins 0.000 claims 9
- 102000039446 nucleic acids Human genes 0.000 claims 9
- 241001465754 Metazoa Species 0.000 claims 7
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 6
- 230000001086 cytosolic effect Effects 0.000 claims 6
- 241000283984 Rodentia Species 0.000 claims 5
- 239000002773 nucleotide Substances 0.000 claims 5
- 125000003729 nucleotide group Chemical group 0.000 claims 5
- 230000001105 regulatory effect Effects 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 4
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 claims 2
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 claims 2
- 102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 claims 2
- 108010075704 HLA-A Antigens Proteins 0.000 claims 2
- 108010058607 HLA-B Antigens Proteins 0.000 claims 2
- 108010052199 HLA-C Antigens Proteins 0.000 claims 2
- 241001529936 Murinae Species 0.000 claims 2
- 102000015736 beta 2-Microglobulin Human genes 0.000 claims 2
- 108010081355 beta 2-Microglobulin Proteins 0.000 claims 2
- 101000937544 Homo sapiens Beta-2-microglobulin Proteins 0.000 claims 1
- 101000986086 Homo sapiens HLA class I histocompatibility antigen, A alpha chain Proteins 0.000 claims 1
- 210000001671 embryonic stem cell Anatomy 0.000 claims 1
- 102000047279 human B2M Human genes 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Environmental Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Engineering & Computer Science (AREA)
- Animal Husbandry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Claims (15)
1. Nukleinska kiselina, naznačena time, da obuhvaća nukleotidnu sekvencu koja kodira kimerni ljudski/ne-ljudski MHC-I-polipeptid, pri čemu nukelotidna sekvenca obuhvaća prvu sekvencu nukleinske kiseline koja kodira domene α1, α2, α3 od ljudskog polipeptida HLA razreda I i drugu sekvencu nukleinske kiseline koja kodira transmembranske i citoplazmatske domene ne-ljudskog MHC-I-polipeptida, tako da nukleotidna sekvenca kodira kimerni ljudski/ne-ljudski MHC-I-polipeptid.
2. Nukleinska kiselina prema zahtjevu 1, naznačena time, da ne-ljudski MHC-I-polipeptid je MHC-I-polipeptid glodavca, te time, da druga sekvenca nukleinske kiseline kodira transmembranske i citoplazmatske domene MHC-I-polipeptida glodavca.
3. Nukleinska kiselina prema zahtjevu 2, naznačena time, da druga sekvenca nukleinske kiseline kodira transmembranske i citoplazmatske domene mišjeg MHC-I-polipeptida, pri čemu mišji MHC-I-polipeptid je opcionalno odabran iz skupine koja se sastoji od H-2K, H-2D i H-2L.
4. Nukleinska kiselina prema bilo kojem od prethodnih zahtjeva, naznačena time, da je ljudski polipeptid HLA-razreda I odabran iz skupine koja se sastoji od HLA-A, HLA-B i HLA-C.
5. Nukleinska kiselina prema bilo kojem od prethodnih zahtjeva, naznačena time, da prva sekvenca nukleinske kiseline kodira domene α1, α2 i α3 ljudskog polipeptida HLA-A (primjerice HLA-A2-polipeptida kao što je HLA-A2.1) i druga sekvenca nukleinske kiseline kodira transmembranske i citoplazmatske domene mišjeg polipeptida H-2K (primjerice H-2Kb-polipeptida).
6. Nukleinska kiselina prema bilo kojem od prethodnih zahtjeva, naznačena time, da nadalje obuhvaća ne-ljudski regulacijski element i vodeću sekvencu, koji su operativno povezani s nukleotidnom sekvencom.
7. Nukleinska kiselina prema zahtjevu 6, naznačena time, da je vodeća sekvenca odabrana od vodeće sekvence ljudskog polipeptida HLA-razreda I, vodeće sekvence ne-ljudskog MHC-I-polipeptida i od njihove kombinacije.
8. Nukleinska kiselina prema zahtjevu 6, naznačena time, da ne-ljudski regulacijski element je glodarski regulacijski element kao što je primjerice mišji regulacijski element.
9. Izolirana stanica, naznačena time, da je ona takva matična stanica embrija koja obuhvaća sekvencu nukleinske kiseline u skladu s bilo kojim od prethodnih zahtjeva.
10. Izolirana stanica prema zahtjevu 9, naznačena time, da stanica na svojoj površini eksprimira kimerni ljudski/ne-ljudski MHC-I-polipeptid.
11. Izolirana stanica prema zahtjevu 9 ili zahtjevu 10, naznačena time, da nadalje obuhvaća nukleotidnu sekvencu koja kodira ljudski ili humanizirani polipeptid β2-mikroglobulina koji je operativno povezan s endogenim ne-ljudskim regulacijskim elementima β2-mikroglobulina.
12. Kimerni ljudski/ne-ljudski, životinjski MHC-I-polipeptid, naznačen time, da ljudski dio kimernog polipetida obuhvaća domene α1, α2 i α3 od ljudskog polipeptida HLA-razreda I i ne-ljudski dio kimernog polipeptida koji obuhvaća transmembranske i citoplazmatske domene ne-ljudskog, životinjskog MHC-I-polipetida, pri čemu je MHC-I-polipetid opcionalno ne-kovalentno vezan na ljudski ili humanizirani β2-mikroglobulin.
13. Kimerni ljudski/ne-ljudski, životinjski MHC-I-polipeptid prema zahtjevu 12, naznačen time, da ne-ljudski, životinjski dio kimernog polipeptida obuhvaća transmembranske i citoplazmatske domene MHC-I-polipetida glodavca (primjerice miša).
14. Kimerni ljudski/ne-ljudski, životinjski MHC-I-polipeptid prema zahtjevu 13, naznačen time, da glodarski MHC-I-polipetid je mišji MHC-I-polipetid koji je odabran iz skupine koja se sastoji od H-2K, H-2D i H-2L, te time, da je ljudski polipeptid HLA-razreda I opcionalno odabran iz skupine koja se sastoji od HLA-A, HLA-B i HLA-C.
15. Kimerni ljudski/ne-ljudski, životinjski MHC-I-polipeptid prema zahtjevu 13 ili 14, naznačen time, da ljudski polipeptid HLA-razreda I je ljudski HLA-A-polipeptid (kao što je HLA-A2-polipeptid, primjerice HLA-A2.1-polipeptid) i ne-ljudski, životinjski MHC-I-polipetid je mišji H-2K-polipeptid (kao što je primjerice H-2Kb-polipeptid).
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161552582P | 2011-10-28 | 2011-10-28 | |
| US201161552587P | 2011-10-28 | 2011-10-28 | |
| US201261700908P | 2012-09-14 | 2012-09-14 | |
| EP17184955.7A EP3262932B1 (en) | 2011-10-28 | 2012-10-26 | Genetically modified major histocompatibility complex mice |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20191420T1 true HRP20191420T1 (hr) | 2019-11-15 |
Family
ID=47178940
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20171761TT HRP20171761T1 (hr) | 2011-10-28 | 2017-11-15 | Genetski modificirani miš s glavnim kompleksom histokompatibilnosti |
| HRP20191420 HRP20191420T1 (hr) | 2011-10-28 | 2019-08-06 | Miševi koji su genetski modificirani s glavnim histokompatibilnim kompleksom |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20171761TT HRP20171761T1 (hr) | 2011-10-28 | 2017-11-15 | Genetski modificirani miš s glavnim kompleksom histokompatibilnosti |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US9615550B2 (hr) |
| EP (4) | EP3262932B1 (hr) |
| JP (4) | JP6154391B2 (hr) |
| KR (3) | KR101921126B1 (hr) |
| CN (3) | CN113564188A (hr) |
| AU (3) | AU2012324016C1 (hr) |
| BR (1) | BR112014009259A2 (hr) |
| CA (2) | CA2850387A1 (hr) |
| CY (2) | CY1119657T1 (hr) |
| DK (2) | DK3262932T3 (hr) |
| ES (3) | ES2741649T3 (hr) |
| HK (2) | HK1200272A1 (hr) |
| HR (2) | HRP20171761T1 (hr) |
| HU (2) | HUE045879T2 (hr) |
| IL (3) | IL232097A (hr) |
| LT (2) | LT3262932T (hr) |
| MX (2) | MX355725B (hr) |
| MY (2) | MY178723A (hr) |
| NZ (1) | NZ734532A (hr) |
| PL (2) | PL3262932T3 (hr) |
| PT (2) | PT3262932T (hr) |
| RS (2) | RS59082B1 (hr) |
| SG (2) | SG10201603188SA (hr) |
| SI (2) | SI2770821T1 (hr) |
| WO (1) | WO2013063346A1 (hr) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2818478T3 (en) | 2011-10-28 | 2017-05-22 | Regeneron Pharma | HUMANIZED IL-6 AND IL-6 RECEPTOR |
| US9591835B2 (en) | 2011-10-28 | 2017-03-14 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex animals |
| LT2958938T (lt) * | 2013-02-20 | 2019-07-25 | Regeneron Pharmaceuticals, Inc. | Pelės, ekspresuojančios humanizuotus t ląstelių koreceptorius |
| US20150342163A1 (en) | 2013-02-22 | 2015-12-03 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex mice |
| HUE041878T2 (hu) * | 2013-02-22 | 2019-06-28 | Regeneron Pharma | Humanizált fõ hisztokompatibilitási komplexet expresszáló egerek |
| EP2967014B1 (en) * | 2013-03-11 | 2019-10-16 | Regeneron Pharmaceuticals, Inc. | Transgenic mice expressing chimeric major histocompatibility complex (mhc) class i molecules |
| CN105592695B (zh) | 2013-09-23 | 2018-04-10 | 瑞泽恩制药公司 | 具有人源化信号调节蛋白基因的非人动物 |
| DK2908626T3 (en) | 2013-10-15 | 2017-03-20 | Regeneron Pharma | Humanized IL-15 animals |
| WO2015056774A1 (ja) * | 2013-10-18 | 2015-04-23 | 大鵬薬品工業株式会社 | Ｈｌａクラスｉ発現非ヒト動物 |
| CN106163273B (zh) | 2014-04-08 | 2020-07-24 | 瑞泽恩制药公司 | 具有人源化FC-γ受体的非人动物 |
| EP3636073B1 (en) | 2014-05-05 | 2023-11-15 | Regeneron Pharmaceuticals, Inc. | Humanized c5 and c3 animals |
| NO2785538T3 (hr) | 2014-05-07 | 2018-08-04 | ||
| RU2735958C2 (ru) | 2014-06-19 | 2020-11-11 | Регенерон Фармасьютикалз, Инк. | Животные, отличные от человека, имеющие гуманизированный ген 1 запрограммированной гибели клеток |
| WO2016044745A1 (en) | 2014-09-19 | 2016-03-24 | Regeneron Pharmaceuticals, Inc. | Chimeric antigen receptors |
| RU2726446C2 (ru) | 2014-11-24 | 2020-07-14 | Регенерон Фармасьютикалз, Инк. | Не относящиеся к человеку животные, экспрессирующие гуманизированный комплекс cd3 |
| AU2015355328B2 (en) | 2014-12-05 | 2022-03-10 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized cluster of differentiation 47 gene |
| HUE052606T2 (hu) | 2014-12-09 | 2021-05-28 | Regeneron Pharma | Humanizált differenciációs klaszter 274 génnel rendelkezõ nem humán állatok |
| CA2969847A1 (en) * | 2014-12-10 | 2016-06-16 | Regents Of The University Of Minnesota | Genetically modified cells, tissues, and organs for treating disease |
| KR20170133498A (ko) | 2015-04-06 | 2017-12-05 | 리제너론 파아마슈티컬스, 인크. | 비인간 동물에서의 인간화 t 세포 매개 면역반응 |
| KR102658190B1 (ko) * | 2015-04-13 | 2024-04-17 | 리제너론 파마슈티칼스 인코포레이티드 | 인간화된 sirpa-il15 녹인 마우스 및 이의 이용 방법 |
| PT3376857T (pt) | 2015-11-20 | 2021-05-27 | Regeneron Pharma | Animais não humanos com um gene humanizado 3 de ativação de linfócitos |
| JP6980674B2 (ja) | 2016-02-29 | 2021-12-15 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | ヒト化ｔｍｐｒｓｓ遺伝子を有する齧歯類 |
| SG10201914014XA (en) | 2016-06-03 | 2020-03-30 | Regeneron Pharma | Non-human animals expressing exogenous terminal deoxynucleotidyltransferase |
| CN109456942A (zh) * | 2017-09-06 | 2019-03-12 | 亘喜生物科技（上海）有限公司 | 通用型嵌合抗原受体t细胞制备技术 |
| CN111386039B (zh) | 2017-09-29 | 2023-02-28 | 瑞泽恩制药公司 | 经基因修饰的啮齿动物基因组 |
| CN116064611A (zh) | 2017-11-30 | 2023-05-05 | 瑞泽恩制药公司 | 包含人源化trkb基因座的非人动物 |
| SG11202008799PA (en) | 2018-03-24 | 2020-10-29 | Regeneron Pharma | Genetically modified non-human animals for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof |
| US11576984B2 (en) | 2018-03-26 | 2023-02-14 | Regeneron Pharmaceuticals, Inc. | Genetically modified mouse with humanized immunoglobulin heavy chain constant region genes and method of using |
| CN112638154B (zh) | 2018-07-16 | 2022-10-18 | 瑞泽恩制药公司 | Ditra疾病的非人动物模型及其用途 |
| CN114206108B (zh) | 2019-04-04 | 2023-09-29 | 瑞泽恩制药公司 | 包括人源化凝血因子12基因座的非人动物 |
| WO2020247452A1 (en) | 2019-06-04 | 2020-12-10 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized ttr locus with a beta-slip mutation and methods of use |
| EP3796776A1 (en) | 2019-06-07 | 2021-03-31 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized albumin locus |
| EP4087392A4 (en) * | 2020-01-10 | 2024-02-21 | Biocytogen Pharmaceuticals Beijing Co Ltd | GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC PROTEIN-MHC COMPLEX |
| WO2022133155A1 (en) * | 2020-12-16 | 2022-06-23 | Xenotherapeutics, Inc. | Humanization of beta2-microglobulin in porcine genome resulting in functional expression of human βeta2-microglobulin within donor cells, tissues, or organs |
| US20240065239A1 (en) | 2020-12-16 | 2024-02-29 | Regeneron Pharmaceuticals, Inc. | Mice expressing humanized fc alpha receptors |
| IL307238A (en) | 2021-03-31 | 2023-11-01 | Regeneron Pharma | Transgenic mice containing human components of the cellular immune system with an enhanced diversity of the TCRB repertoire |
| WO2023240109A1 (en) | 2022-06-07 | 2023-12-14 | Regeneron Pharmaceuticals, Inc. | Multispecific molecules for modulating t-cell activity, and uses thereof |
| WO2023240124A1 (en) | 2022-06-07 | 2023-12-14 | Regeneron Pharmaceuticals, Inc. | Pseudotyped viral particles for targeting tcr-expressing cells |
| US20240099279A1 (en) | 2022-09-22 | 2024-03-28 | Regeneron Pharmaceuticals, Inc. | Genetically modified mice expressing components of human cellular immune system |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| ATE423195T1 (de) | 1989-07-25 | 2009-03-15 | Cell Genesys Inc | Homologe rekombination für universelle donorzellen und chimerische säugetierzellen |
| US5574205A (en) | 1989-07-25 | 1996-11-12 | Cell Genesys | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| GB9100481D0 (en) | 1991-01-10 | 1991-02-20 | Inst Nat Sante Rech Med | Genetically engineered mice |
| AU2661692A (en) | 1991-09-19 | 1993-04-27 | President And Fellows Of Harvard College | Transgenic mhc class i and class ii antigen-deficient mammals |
| EP0663952A4 (en) | 1992-09-11 | 1997-06-11 | Univ California | TRANSGENIC NON-HUMAN ANIMALS WITH TARGETED INTERRUPTED TRANSDUCTION GENES IN LYMPHOCYTES. |
| US5523226A (en) | 1993-05-14 | 1996-06-04 | Biotechnology Research And Development Corp. | Transgenic swine compositions and methods |
| GB9315303D0 (en) | 1993-07-23 | 1993-09-08 | Zeneca Ltd | Polypeptide |
| US5965787A (en) | 1995-08-31 | 1999-10-12 | Mayo Foundation For Medical Education And Research | HLA-DRBI peptides with specific binding affinity for HLA-DQ molecules: prevention and treatment of rheumatoid arthritis |
| US6002066A (en) | 1996-01-16 | 1999-12-14 | Ortho Pharmaceutical Corp. | H2-M modified transgenic mice |
| EP0910409A4 (en) | 1996-03-05 | 2003-03-19 | Scripps Research Inst | RECOMBINANT ELEMENTS ENCODING FOR T-LYMPHOCYTE RECEPTORS SPECIFIC TO HLA HUMAN BOUNDARY TUMOR ANTIGENS |
| EP1500329B1 (en) | 1996-12-03 | 2012-03-21 | Amgen Fremont Inc. | Human antibodies that specifically bind human TNF alpha |
| ATE423789T1 (de) | 1997-09-16 | 2009-03-15 | Univ Oregon Health & Science | Rekombinante mhc-moleküle welche nützlich sind für die manipulation von antigen-spezifischen t- zellen |
| US6372955B1 (en) | 1998-02-17 | 2002-04-16 | Ortho Mcneil Pharmaceutical, Inc. | Methods for Producing B cells and antibodies from H2-O modified transgenic mice |
| AU1023401A (en) * | 1999-10-12 | 2001-04-23 | Institut Pasteur | Design of a polyepitopic construct for the induction of hla-a2.1 restricted hiv 1 specific ctl responses using hhd mice |
| US7105348B2 (en) | 2000-10-31 | 2006-09-12 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| JPWO2002047474A1 (ja) | 2000-12-13 | 2004-04-15 | 住友製薬株式会社 | Ｈｌａ−ａ２４発現トランスジェニック動物及びその利用 |
| EP1409646B1 (en) | 2000-12-19 | 2012-06-13 | Altor BioScience Corporation | Transgenic animals comprising a humanized immune system |
| FR2827302B1 (fr) * | 2001-07-13 | 2003-10-10 | Genoway | Cellule et animal transgenique modelisant la presentation antigenique humaine et leurs utilisations |
| US8895020B2 (en) | 2002-04-19 | 2014-11-25 | Washington University | Single chain trimers and uses therefor |
| US7179645B2 (en) * | 2002-09-24 | 2007-02-20 | Antigen Express, Inc. | Ii-Key/antigenic epitope hybrid peptide vaccines |
| US7663017B2 (en) * | 2003-07-30 | 2010-02-16 | Institut Pasteur | Transgenic mice having a human major histocompatability complex (MHC) phenotype, experimental uses and applications |
| WO2005085438A1 (ja) | 2004-03-09 | 2005-09-15 | Nagoya Industrial Science Research Institute | ヒト関節リウマチの病態を再現するトランスジェニック非ヒト哺乳動物 |
| DK2767161T3 (en) | 2004-10-19 | 2018-05-07 | Regeneron Pharma | Method of generating an animal homozygous for genetic modification |
| JP4830139B2 (ja) * | 2006-03-10 | 2011-12-07 | 学校法人明治大学 | クローン胚の作製方法 |
| NZ547859A (en) * | 2006-06-09 | 2009-05-31 | Dec Int Nz Ltd | Treatment method and composition for mastitis |
| EP1878798A1 (en) | 2006-07-13 | 2008-01-16 | Institut Pasteur | Method of producing a multichimeric mouse and applications to study the immunopathogenesis of human tissue-specific pathologies |
| EP1878342A1 (en) * | 2006-07-13 | 2008-01-16 | Institut Pasteur | Immunodeficient mice transgenic for HLA class I and HLA class II molecules and their uses |
| EP2152750A1 (en) * | 2007-04-23 | 2010-02-17 | Schering Corporation | Anti-mdl-1 antibodies |
| WO2009114400A1 (en) | 2008-03-07 | 2009-09-17 | Regeneron Pharmaceuticals, Inc. | Es cell-derived mice from diploid host embryo injection |
| US20090328240A1 (en) | 2008-06-24 | 2009-12-31 | Sing George L | Genetically modified mice as predictors of immune response |
| EP2153845A1 (en) * | 2008-08-13 | 2010-02-17 | Julius-Maximilians-Universität Würzburg | Endoglin peptides, vaccines and methods for preparing the same |
| LT3241435T (lt) * | 2009-07-08 | 2021-10-25 | Kymab Limited | Gyvūnų modeliai ir terapinės molekulės |
| WO2012039779A1 (en) | 2010-09-24 | 2012-03-29 | The United States Of America As Represented By The Secretary Of The Navy | Humanized transgenic mouse model |
| LT2958938T (lt) | 2013-02-20 | 2019-07-25 | Regeneron Pharmaceuticals, Inc. | Pelės, ekspresuojančios humanizuotus t ląstelių koreceptorius |
| US20150342163A1 (en) | 2013-02-22 | 2015-12-03 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex mice |
| HUE041878T2 (hu) | 2013-02-22 | 2019-06-28 | Regeneron Pharma | Humanizált fõ hisztokompatibilitási komplexet expresszáló egerek |
| KR20170133498A (ko) | 2015-04-06 | 2017-12-05 | 리제너론 파아마슈티컬스, 인크. | 비인간 동물에서의 인간화 t 세포 매개 면역반응 |
-
2012
- 2012-10-26 EP EP17184955.7A patent/EP3262932B1/en active Active
- 2012-10-26 KR KR1020147014476A patent/KR101921126B1/ko active IP Right Grant
- 2012-10-26 CN CN202110831383.7A patent/CN113564188A/zh active Pending
- 2012-10-26 PT PT17184955T patent/PT3262932T/pt unknown
- 2012-10-26 ES ES17184955T patent/ES2741649T3/es active Active
- 2012-10-26 DK DK17184955.7T patent/DK3262932T3/da active
- 2012-10-26 SI SI201231136T patent/SI2770821T1/en unknown
- 2012-10-26 ES ES19167619T patent/ES2962287T3/es active Active
- 2012-10-26 RS RS20190998A patent/RS59082B1/sr unknown
- 2012-10-26 EP EP19167619.6A patent/EP3563680B1/en active Active
- 2012-10-26 WO PCT/US2012/062042 patent/WO2013063346A1/en active Application Filing
- 2012-10-26 BR BR112014009259-1A patent/BR112014009259A2/pt not_active Application Discontinuation
- 2012-10-26 CN CN201280060540.8A patent/CN104039132B9/zh active Active
- 2012-10-26 KR KR1020187033187A patent/KR102074145B1/ko active IP Right Grant
- 2012-10-26 ES ES12787255.4T patent/ES2651517T3/es active Active
- 2012-10-26 PT PT127872554T patent/PT2770821T/pt unknown
- 2012-10-26 NZ NZ734532A patent/NZ734532A/en unknown
- 2012-10-26 CA CA2850387A patent/CA2850387A1/en active Pending
- 2012-10-26 LT LTEP17184955.7T patent/LT3262932T/lt unknown
- 2012-10-26 DK DK12787255.4T patent/DK2770821T3/da active
- 2012-10-26 HU HUE17184955A patent/HUE045879T2/hu unknown
- 2012-10-26 JP JP2014539029A patent/JP6154391B2/ja active Active
- 2012-10-26 LT LTEP12787255.4T patent/LT2770821T/lt unknown
- 2012-10-26 AU AU2012324016A patent/AU2012324016C1/en active Active
- 2012-10-26 US US13/661,159 patent/US9615550B2/en active Active
- 2012-10-26 MY MYPI2017703836A patent/MY178723A/en unknown
- 2012-10-26 MX MX2014004895A patent/MX355725B/es active IP Right Grant
- 2012-10-26 CA CA3074400A patent/CA3074400A1/en active Pending
- 2012-10-26 PL PL17184955T patent/PL3262932T3/pl unknown
- 2012-10-26 PL PL12787255T patent/PL2770821T3/pl unknown
- 2012-10-26 MY MYPI2014000784A patent/MY164836A/en unknown
- 2012-10-26 HU HUE12787255A patent/HUE035652T2/en unknown
- 2012-10-26 RS RS20171195A patent/RS56656B1/sr unknown
- 2012-10-26 CN CN201710347715.8A patent/CN107254480B/zh active Active
- 2012-10-26 SG SG10201603188SA patent/SG10201603188SA/en unknown
- 2012-10-26 SG SG11201400933VA patent/SG11201400933VA/en unknown
- 2012-10-26 KR KR1020207002887A patent/KR102295746B1/ko active IP Right Grant
- 2012-10-26 SI SI201231650T patent/SI3262932T1/sl unknown
- 2012-10-26 MX MX2020010763A patent/MX2020010763A/es unknown
- 2012-10-26 EP EP12787255.4A patent/EP2770821B1/en active Active
- 2012-10-26 EP EP23193595.8A patent/EP4311833A3/en active Pending
-
2014
- 2014-04-13 IL IL232097A patent/IL232097A/en active IP Right Grant
-
2015
- 2015-01-29 HK HK15101011.6A patent/HK1200272A1/xx unknown
-
2016
- 2016-04-27 AU AU2016202688A patent/AU2016202688B2/en active Active
-
2017
- 2017-02-22 US US15/439,828 patent/US10869466B2/en active Active
- 2017-04-30 IL IL252022A patent/IL252022A0/en active IP Right Grant
- 2017-06-01 JP JP2017109327A patent/JP6574457B2/ja active Active
- 2017-11-15 HR HRP20171761TT patent/HRP20171761T1/hr unknown
- 2017-11-22 CY CY20171101223T patent/CY1119657T1/el unknown
- 2017-12-22 AU AU2017279797A patent/AU2017279797C1/en active Active
-
2018
- 2018-06-29 HK HK18108466.8A patent/HK1249712B/zh unknown
- 2018-08-20 IL IL26123918A patent/IL261239B/en active IP Right Grant
-
2019
- 2019-02-06 JP JP2019019707A patent/JP6866409B2/ja active Active
- 2019-08-06 HR HRP20191420 patent/HRP20191420T1/hr unknown
- 2019-08-07 CY CY20191100840T patent/CY1121869T1/el unknown
-
2020
- 2020-05-07 JP JP2020081774A patent/JP2020146041A/ja not_active Withdrawn
- 2020-08-12 US US16/991,283 patent/US20200375160A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20191420T1 (hr) | Miševi koji su genetski modificirani s glavnim histokompatibilnim kompleksom | |
| HRP20191280T1 (hr) | Miševi koji eksprimiraju ko-receptore humanizirane t-stanice | |
| HRP20220616T1 (hr) | Genetski modificirani miš koji eksprimira kimerne molekule glavnog kompleksa histokompatibilnosti (mhc) ii | |
| JP2014532412A5 (hr) | ||
| BR112018067698A2 (pt) | células modificadas para imunoterapia | |
| CO2017006808A2 (es) | Receptores de antígenos quiméricos de bcma | |
| HRP20211455T1 (hr) | Životinje s humaniziranim il-4 i il-4r alfa | |
| PA8672101A1 (es) | Anticuerpos anti-il-6, composiciones, métodos y usos | |
| FI3280257T3 (fi) | Humanisoituja t-soluvälitteisiä immuunivasteita ei-ihmiseläimillä | |
| BR112012027917A2 (pt) | anticorpos que apresentam reduzida imunogenicidade em um indivíduo humano | |
| BR112017005390A2 (pt) | células citotóxicas alvo com receptores quiméricos para imunoterapia adotiva | |
| HRP20192311T1 (hr) | Adam6 miševi | |
| JP2016510998A5 (hr) | ||
| BR112017010793A2 (pt) | animal não humano geneticamente modificado, camundongo, métodos para produzir um animal não humano geneticamente modificado e de triagem de candidatos a fármaco direcionados a um antígeno de interesse, e, modelo de camundongo. | |
| BR112016011003A2 (pt) | animal roedor geneticamente modificado, célula tronco embrionária de camundongo, embrião de camundongo, e, métodos para fabricar um animal roedor e para enxertar células humanas em um camundongo | |
| CY1123046T1 (el) | Ζωα εκτος του ανθρωπου που εχουν ανθρωποποιημενους υποδοχεις fc-γ | |
| PA8830701A1 (es) | Anticuerpos contra il-6 y sus usos | |
| BR112016011004A2 (pt) | animal roedor geneticamente modificado, célula tronco embrionária de roedor, embrião de roedor, e, métodos para fabricar um animal roedor e para enxertar células humanas em um camundongo | |
| MX2021014818A (es) | Anticuerpos monoclonales anti-cd303. | |
| EP4249507A3 (en) | Transgenic mice expressing chimeric major histocompatibility complex (mhc) class ii molecules | |
| BR112021018788A2 (pt) | Células, tecidos e órgãos personalizados para transplante de um doador (não humano) humanizado, indivi-dualizado, designado livre de patógenos e métodos e produtos relacionados aos mesmos | |
| MA33935B1 (fr) | Animal non humain transgénique et utilisations de celui-ci | |
| Alibekov et al. | Minimizing the Negative Impact on Wildlife During Filling of the Lower Bureya HPP Reservoir in the Amur Oblast | |
| TH168664A (th) | หนูที่มีเมเจอร์ ฮิสโตคอมแพทาบิลิตี้ คอมเพลกซ์ซึ่งถูกดัดแปลงทางพันธุกรรม | |
| Coll | Global Ecological Modelling to Simulate Future Trajectories of Change in Marine Ecosystems |